Barclays PLC Mirati Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$41.99 - $62.38 $15.3 Million - $22.7 Million	364,571 Added 285.32%	492,345 $28.9 Million
Q3 2023 Nov 07, 2023	BUY	$27.8 - $45.35 $664,503 - $1.08 Million	23,903 Added 23.01%	127,774 $5.57 Million
Q2 2023 Aug 03, 2023	SELL	$36.13 - $49.49 $1.37 Million - $1.88 Million	-37,989 Reduced 26.78%	103,871 $3.75 Million
Q1 2023 May 04, 2023	SELL	$36.54 - $54.26 $3.16 Million - $4.7 Million	-86,565 Reduced 37.9%	141,860 $5.28 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $4.18 Million - $9.99 Million	101,331 Added 79.73%	228,425 $10.4 Million
Q3 2022 Nov 03, 2022	BUY	$59.5 - $86.7 $6.85 Million - $9.99 Million	115,181 Added 966.85%	127,094 $8.88 Million
Q2 2022 Aug 12, 2022	SELL	$39.16 - $88.71 $480,219 - $1.09 Million	-12,263 Reduced 50.72%	11,913 $800,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $628,851 - $1.25 Million	-8,294 Reduced 25.54%	24,176 $1.99 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $2.29 Million - $3.31 Million	17,374 Added 115.09%	32,470 $4.76 Million
Q3 2021 Nov 09, 2021	SELL	$132.13 - $177.45 $1.98 Million - $2.66 Million	-14,994 Reduced 49.83%	15,096 $2.67 Million
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $1.32 Million - $1.65 Million	-9,175 Reduced 23.37%	30,090 $4.86 Million
Q1 2021 May 13, 2021	BUY	$158.92 - $221.61 $148,749 - $207,426	936 Added 2.44%	39,265 $6.73 Million
Q4 2020 Feb 11, 2021	SELL	$162.05 - $240.27 $8.9 Million - $13.2 Million	-54,938 Reduced 58.9%	38,329 $8.42 Million
Q3 2020 Nov 12, 2020	BUY	$113.26 - $167.27 $597,106 - $881,847	5,272 Added 5.99%	93,267 $15.5 Million
Q2 2020 Aug 12, 2020	SELL	$72.01 - $120.39 $1.32 Million - $2.21 Million	-18,370 Reduced 17.27%	87,995 $10 Million
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $3.36 Million - $5.6 Million	48,194 Added 82.85%	106,365 $8.18 Million
Q4 2019 Feb 10, 2020	BUY	$70.76 - $128.86 $2.6 Million - $4.74 Million	36,799 Added 172.18%	58,171 $7.5 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $975,822 - $1.37 Million	-12,525 Reduced 36.95%	21,372 $1.67 Million
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $1.16 Million - $2.04 Million	-19,462 Reduced 36.47%	33,897 $3.49 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $591,719 - $1.07 Million	13,556 Added 34.06%	53,359 $3.91 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $777,600 - $1.15 Million	24,300 Added 156.74%	39,803 $1.69 Million
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $477,970 - $636,279	-10,148 Reduced 39.56%	15,503 $730,000
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $379,001 - $762,367	-14,549 Reduced 36.19%	25,651 $1.27 Million
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $381,840 - $775,890	22,200 Added 123.33%	40,200 $1.23 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $69,575 - $104,500	5,500 Added 44.0%	18,000 $328,000
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $58,750 - $146,250	12,500	12,500 $146,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account